We are preparing the requested document. Please wait, this may take a while...!
|Antigen||V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) Antibodies|
|Epitope||Extracellular Domain Alternatives|
|Conjugate||This HER2 antibody is un-conjugated Alternatives|
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
|Supplier||Log in to see|
Product Details anti-HER2 AntibodyTarget Details HER2 Application Details Handling Images
|Purpose||This antibody is designed for the specific localization of human c-erbB-2 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections. This antibody is recommended to determine the levels of expression of the oncoprotein c-erbB-2 in adenocarcinomas of breast, lung and other locations and transitional cell carcinomas of the urinary tract. Immunohistochemical staining of this oncoprotein is associated with gene amplification. In the case of breast cancer, overexpression of this oncoprotein has been shown to be associated with a worse prognosis.|
|Characteristics||The gene product HER-2/neu (also known as c-erbB-2 gene product, p185 or CD380) belongs to the protein family of epidermal growth factor receptors. It is a 185 kDa transmembrane glycoprotein with tyrosine kinase activity. Some adenocarcinomas including carcinomas of the gastrointestinal tract and ovarian carcinomas as well as up to 30% of all breast carcinomas are showing an overexpression of HER2. It was shown that overexpression of HER2 is correlated with bad prognosis. Similar observations were made for osteosarcomas as well as stomach and bladder carcinomas. Proof of HER2 overexpression in breast carcinoma is regarded to be necessary for a therapy with Trastuzumab (Herceptin™). The antibody clone SP3 is directed against the extracellular domain of the HER2 protein. Immunohistochemistry (IHC) is a complex technique in which immunological and histological detection methods are combined. In general, the manipulation and processing of tissues before immunostaining, especially different types of tissue fixation and embedding, as well as the nature of the tissues themselves may cause inconsistent results (Nadji and Morales, 1983). Endogenous pseudoperoxidase and peroxidase activity or endogenous biotin and alkaline phosphatase activity can cause non-specific staining results depending on the detection system used. Tissues that contain Hepatitis B surface antigen (HBsAg) can produce false positives when using HRP detection systems (Omata et al, 1980). Insufficient contrast staining and/or improper mounting of the sample may influence the interpretation of results.|
|Purification||Ready-to-use, Prediluted, obtained from culture supernatant|
|Material not included||All reagents, materials, and laboratory equipment for IHC procedures are not provided with this antibody. This includes adhesive slides and cover slips, positive and negative control tissues, Xylene or adequate substitute, ethanol, distilled H2O, heat pretreatment equipment (pressure cooker, steamer, microwave), pipettes, Coplin jars, glass jars, moist chamber, histological baths, negative control reagents, counter-staining solution, mounting materials, and microscope. Buffered solutions for antigen retrieval, enzyme treatments, highly sensitive detection systems, and other auxiliary Anti- c-erbB-2/HER2/neu (|
|Immunogen||Recombinant protein corresponding to the extracellular domain of human HER2 protein.|
|Plasmids, Primers & others|
Target Details HER2Product Details anti-HER2 Antibody Application Details Handling Images back to top
|Alternative Name||c-erbB-2 (ERBB2 Antibody Abstract)|
|Pathways||RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development|
Application DetailsProduct Details anti-HER2 Antibody Target Details HER2 Handling Images back to top
Staining pattern: Cell membrane. The interpretation of the stain results is the full responsibility of the user. Any experimental result must be confirmed by a medically established diagnostic product or procedure.
Principles of the procedure: The demonstrations of antigens by IHC is a sequential procedure with several steps involving first the application of a specific antibody for the antigen of interest (primary antibody), then a secondary antibody which joins to the first, an enzyme complex, and the addition of a chromogenic substrate. The sample is washed between each step. Enzymatic activation of the chromogenic substrate creates a visible product where the antigen is located. The results are interpreted using a light microscope. The primary antibody can be used both in manual IHC and with automated immunostainers.
Paraffin-embedded tissue samples should be used. The antibody is also useful for immunostaining frozen tissue samples. Western blot techniques are not recommended.
Antigen retrieval: HIER Citrate Buffer pH 6.5
Working dilution: (only for concentrates) 1:50 – 1:200
Incubation: 30 min, RT
Control Tissue: Breast carcinoma with overexpression of c-erbB-2
|Restrictions||For Research Use only|
HandlingProduct Details anti-HER2 Antibody Target Details HER2 Application Details Images back to top
|Buffer||The preparation contains saline buffer, stabilising and carriers proteins. (pH 7.4)|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage Comment||Store at 2-8 °C until the expiration date printed on product label. Do not use after the expiration date. If fresh solutions are required, these must be prepared immediately prior to use, and will be stable for at least one day at room temperature (20-25°C). Unused portion of antibody preparation should be discarded after one day.If the product is stored under different conditions from those stipulated in these technical indications, the new conditions must be verified by the user. The validity period of the ready to use products when opened, is the same as the expiration date indicated on the label of intact product.|